Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-094386
Filing Date
2025-07-07
Accepted
2025-07-07 19:11:11
Documents
1
Period of Report
2025-07-03

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7168
  Complete submission text file 0000950170-25-094386.txt   8891
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Issuer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE FIRST AVENUE, PARRIS BUILDING 34 NAVY YARD PLAZA BOSTON MA 02129
Business Address
Vieser Jaime (Reporting) CIK: 0001846045 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33038 | Film No.: 251109276